$MEDS TRxADE HEALTH, INC. Announces Resumption of Modified Stock Repurchase Program
https://www.accesswire.com/677127/TRxADE-HEAL...se-Program
TAMPA, FL / ACCESSWIRE / December 13, 2021 / TRxADE HEALTH, INC. (NASDAQ:MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced that its Board of Directors has authorized the resumption of the previously disclosed stock repurchase program, which was modified by the Board of Directors to allow for the repurchase of up to a maximum of 100,000 shares of the Company's common stock, originally approved in May 2021, which was paused while the Company's ‘at-the-market' offering was ongoing, and which ‘at-the-market' offering was recently terminated. There is no time frame for the repurchase program, and such program will remain in place until a maximum of 100,000 shares of the Company's common stock has been repurchased or until such program is discontinued by the Board of Directors.
Under the stock repurchase program, shares may be repurchased from time to time in the open market or through negotiated transactions at prevailing market rates, or by other means in accordance with federal securities laws. Repurchases will be made at management's discretion at prices management considers to be attractive and in the best interests of both the Company and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company's financial performance. Open market purchases will be conducted in accordance with the limitations set forth in Rule 10b-18 of the Securities Exchange Act of 1934 and other applicable legal requirements. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws.
The repurchase program may be suspended, paused, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any particular number of shares. There is no guarantee as to the exact number or value of shares that will be repurchased by the Company, if any.
The repurchase program will be funded using the Company's working capital. As of September 30, 2021, the Company had cash of approximately $3.6 million. The Company currently has 8,166,457 shares of common stock issued and outstanding.
All shares purchased by the Company under the stock repurchase program will be retired and returned to treasury.
https://www.accesswire.com/677127/TRxADE-HEAL...se-Program
TAMPA, FL / ACCESSWIRE / December 13, 2021 / TRxADE HEALTH, INC. (NASDAQ:MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced that its Board of Directors has authorized the resumption of the previously disclosed stock repurchase program, which was modified by the Board of Directors to allow for the repurchase of up to a maximum of 100,000 shares of the Company's common stock, originally approved in May 2021, which was paused while the Company's ‘at-the-market' offering was ongoing, and which ‘at-the-market' offering was recently terminated. There is no time frame for the repurchase program, and such program will remain in place until a maximum of 100,000 shares of the Company's common stock has been repurchased or until such program is discontinued by the Board of Directors.
Under the stock repurchase program, shares may be repurchased from time to time in the open market or through negotiated transactions at prevailing market rates, or by other means in accordance with federal securities laws. Repurchases will be made at management's discretion at prices management considers to be attractive and in the best interests of both the Company and its stockholders, subject to the availability of stock, general market conditions, the trading price of the stock, alternative uses for capital, and the Company's financial performance. Open market purchases will be conducted in accordance with the limitations set forth in Rule 10b-18 of the Securities Exchange Act of 1934 and other applicable legal requirements. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws.
The repurchase program may be suspended, paused, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any particular number of shares. There is no guarantee as to the exact number or value of shares that will be repurchased by the Company, if any.
The repurchase program will be funded using the Company's working capital. As of September 30, 2021, the Company had cash of approximately $3.6 million. The Company currently has 8,166,457 shares of common stock issued and outstanding.
All shares purchased by the Company under the stock repurchase program will be retired and returned to treasury.
